For successful human leukocyte antigen-incompatible (HLAi) or ABO-incompatible (ABOi) living-donor kidney transplantations (LDKTs), pretransplant desensitization is essential; however, early antibody-mediated rejection (ABMR) remains the most important complication after HLAi or ABOi transplantation. Here, we report a case of early acute ABMR in simultaneous HLAi and ABOi LDKT with preformed donor-specific antibody (DSA), despite desensitization. Dialysis-dependent, severe ABMR occurred with a rebound of pre-existing DSA and appearance of de novo DSA after initial normalization of renal function, 8 days postoperatively. However, a low anti-ABO antibody titer (1:8) was maintained after transplantation. Combination therapy of plasmapheresis, high-dose intravenous immunoglobulin, and bortezomib improved both ABMR and renal functions.
INTRODUCTION
Donor shortage is responsible for the increase in the number of human leukocyte antigen-incompatible (HLAi) and ABO-incompatible (ABOi) living-donor kidney transplantation (LDKT) cases in Korea. For successful HLAi or ABOi LDKT, it is necessary to perform pretransplant desensitization; however, early antibody-mediated rejection (ABMR) is still the most important complication following HLAi or ABOi transplantation. ABMR is an immune response of alloantibodies against the transplanted organ, more specifically against mismatched classical HLA antigens of a donor, nonclassical major histocompatibility complex class I-related chain-A antibodies, non-HLA endothelial antigens, or mismatched ABO antigens [1] [2] [3] . Acute ABMR is a major cause for graft loss in kidney transplantation [1] . Here, we described a case of early acute ABMR after HLAi and ABOi LDKT, treated by a combination therapy of plasmapheresis, high-dose intravenous immunoglobulin (IV-Ig), and bortezomib. . Pathology of kidney biopsy on postoperative day 28 (POD28). Kidney biopsy on POD28 showed antibody-mediated rejection (ABMR) grade-II as per Banff classification 2017 (t0, i0, iIFTA0, g1, ptc1, v1, ci0, ct0, cg3, mm1, cv1, ah0, aah0, c4d2). According to Banff 2013 classification of acute ABMR in renal allografts, three criteria have to be met for diagnosing ABMR. For tissue injury compatible with ABMR, conditions include microvascular injury, intimal or transmural arteritis, acute thrombotic microangiopathy without other cause, and acute tubular injury without any other cause. Presence of donor-specific antibody (e.g., human leukocyte antigen-incompatible or other antigens) is needed for confirming ABMR. Evidence of their interaction with the vascular endothelium is needed, which include linear C4d staining of peritubular capillaries, at least moderate microvascular injury, and molecular markers [4] . Two days after the tenth plasmapheresis session, the patient underwent LDKT and administration of anti-thy- cg3, mm1, cv1, ah0, aah0, c4d2) ( Fig. 1) despite appropriate desensitization [9] .
Acute ABMR occurs in approximately 5% HLAc LDKT patients, but its incidence can increase to 50% in HLAi LDKT patients [10] . Acute ABMR can cause 1-year graft loss in 15%-20% patients and exhibits worse prognosis than that of acute T cell-mediated rejection. It occurs in the first few days per weeks after transplantation and is less responsive to anti-rejection therapy; therefore, it could easily cause chronic allograft dysfunction and graft loss. The 5-year graft survival rate was 60% and 92.5% among patients with and without ABMR, respectively. For long-term survival of the graft, its prevention and treatment is important [1, 11] , and it is also a major hurdle to overcome in LDKT. Similar to this case, early ABMR usually occurs within the first few days/weeks after HLAi or ABOi LDKT in sensitized patients [12] . Memory B-cells stimulated by alloantigen rapidly increase the preformed DSA levels, and the incidence of early ABMR is closely linked to the DSA level at that time. The incidence is as high as 40% in patients with high DSA levels, whereas it is ＜10% in those with low DSA levels [13] . Anti-ABO antibody titer higher than 1:32 is associated with a higher ABMR rate in ABOi KT. We need to reduce the preformed DSA and anti-ABO antibody levels before HLAi or ABOi LDKT and maintain them at low levels after LDKT. Anti-ABO antibodies cannot induce overt ABMR when they are maintained at low levels during the initial 3-4 weeks, especially after ABOi LDKT, and this phenomenon is called accommodation. It explains the better prognosis of ABOi KT than that of HLAi KT, and emphasizes the importance of controlling the DSA levels rather than an- These results suggested that DSA is a more important risk factor than anti-ABO antibody for ABMR in simultaneous HLAi and ABOi LDKT, and timely treatment can rescue even dialysis-dependent, severe ABMR.
This extreme but rare case of early severe ABMR following simultaneous HLAi and ABOi LDKT emphasizes the focus on rebound DSA and risk of early ABMR, despite a successful initial posttransplant clinical course after desensitization. DSA rebound in this case could be attributed to the booster immune response of memory B-cells that were not completely depleted in the lymph nodes by rituximab treatment or the long-lived plasma cells in the bone marrow that were resistant to bortezomib or were replenished by humoral compensation [4, 13] . Humoral compensation indicates that increased germinal center B-cells and follicular helper T-cells under B-cell activating factor (BAFF) can replenish plasma cells again after initial depletion [1, 4] . Therefore, combination of bortezomib with BAFF inhibitors or belatacept that interferes with B-T interaction could be used to overcome humoral compensation for refractory DSA [15] . Due to this limitation of the current regimens, it is essential to monitor DSA and anti-ABO levels in HLAi or ABOi LDKT during the initial 3-4 weeks after desensitization.
